nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully achieved the primary endpoint for the nanoMesh™ Pathogen Inhibiting Protein (PIP) uptake studies. The PIP trials demonstrated strong uptake1 of a series of pathogen inhibiting proteins2, including casein3,4,5,6 and mucin7 by nanoMesh™.
nanoMesh™ possesses a unique nanometer-level surface texture, via the application of Accelerated Neutral Atom Beam (ANAB) technology8 during manufacturing.
nanoMesh™ is indicated for the repair of abdominal wall hernias and abdominal wall deficiencies that require the addition of reinforcing material to obtain the desired surgical result.
nanoMesh™ is commercially available in the US9. nanoMesh™ has now been shown to solicit the adsorption of proteins known to be inhibitory to the attachment of bacteria.